Unknown

Dataset Information

0

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.


ABSTRACT: BackgroundResponses to conventional donor lymphocyte infusion for postallogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse.MethodsWe initiated this ongoing phase I trial of adoptively transferred cytokine-induced memory-like (CIML) NK cells in patients with myeloid malignancies who relapsed after haploidentical HCT. All patients received a donor-derived NK cell dose of 5 to 10 million cells/kg after lymphodepleting chemotherapy, followed by systemic IL-2 for 7 doses. High-resolution profiling with mass cytometry and single-cell RNA sequencing characterized the expanding and persistent NK cell subpopulations in a longitudinal manner after infusion.ResultsIn the first 6 enrolled patients on the trial, infusion of CIML NK cells led to a rapid 10- to 50-fold in vivo expansion that was sustained over months. The infusion was well tolerated, with fever and pancytopenia as the most common adverse events. Expansion of NK cells was distinct from IL-2 effects on endogenous post-HCT NK cells, and not dependent on CMV viremia. Immunophenotypic and transcriptional profiling revealed a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires.ConclusionGiven their rapid expansion and long-term persistence in an immune-compatible environment, CIML NK cells serve as a promising platform for the treatment of posttransplant relapse of myeloid disease. Further characterization of their unique in vivo biology and interaction with both T cells and tumor targets will lead to improvements in cell-based immunotherapies.Trial RegistrationClinicalTrials.gov NCT04024761.FundingDunkin' Donuts, NIH/National Cancer Institute, and the Leukemia and Lymphoma Society.

SUBMITTER: Shapiro RM 

PROVIDER: S-EPMC9151697 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.

Shapiro Roman M RM   Birch Grace C GC   Hu Guangan G   Vergara Cadavid Juliana J   Nikiforow Sarah S   Baginska Joanna J   Ali Alaa K AK   Tarannum Mubin M   Sheffer Michal M   Abdulhamid Yasmin Z YZ   Rambaldi Benedetta B   Arihara Yohei Y   Reynolds Carol C   Halpern Max S MS   Rodig Scott J SJ   Cullen Nicole N   Wolff Jacquelyn O JO   Pfaff Kathleen L KL   Lane Andrew A AA   Lindsley R Coleman RC   Cutler Corey S CS   Antin Joseph H JH   Ho Vincent T VT   Koreth John J   Gooptu Mahasweta M   Kim Haesook T HT   Malmberg Karl-Johan KJ   Wu Catherine J CJ   Chen Jianzhu J   Soiffer Robert J RJ   Ritz Jerome J   Romee Rizwan R  

The Journal of clinical investigation 20220601 11


BackgroundResponses to conventional donor lymphocyte infusion for postallogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse.MethodsWe initiated this ongoing phase I trial of adoptively transferred cytokine-induced memory-like (CIML) NK cells in patients with myeloid malignancies who relapsed after haploidentical HCT. All patients received a donor-derived NK cell dose of 5 to 10 mill  ...[more]

Similar Datasets

2022-03-11 | GSE198141 | GEO
| PRJNA813854 | ENA
| S-EPMC8727305 | biostudies-literature
| S-EPMC5486172 | biostudies-literature
| S-EPMC5873230 | biostudies-literature
| S-EPMC4537797 | biostudies-literature
| S-EPMC5462891 | biostudies-literature
| S-EPMC4410097 | biostudies-literature
| S-EPMC8931511 | biostudies-literature
| S-EPMC9210521 | biostudies-literature